KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Neogenomics (NEO) Equity Ratio (2016 - 2025)

Neogenomics (NEO) has disclosed Equity Ratio for 16 consecutive years, with 0.62 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Equity Ratio rose 11.68% year-over-year to 0.62, compared with a TTM value of 0.62 through Dec 2025, up 11.68%, and an annual FY2025 reading of 0.62, up 11.68% over the prior year.
  • Equity Ratio was 0.62 for Q4 2025 at Neogenomics, up from 0.61 in the prior quarter.
  • Across five years, Equity Ratio topped out at 0.62 in Q4 2025 and bottomed at 0.55 in Q4 2024.
  • Average Equity Ratio over 5 years is 0.58, with a median of 0.57 recorded in 2022.
  • The sharpest move saw Equity Ratio tumbled 97.87% in 2021, then increased 11.68% in 2025.
  • Year by year, Equity Ratio stood at 0.59 in 2021, then dropped by 3.23% to 0.57 in 2022, then decreased by 2.36% to 0.56 in 2023, then dropped by 1.64% to 0.55 in 2024, then grew by 11.68% to 0.62 in 2025.
  • Business Quant data shows Equity Ratio for NEO at 0.62 in Q4 2025, 0.61 in Q3 2025, and 0.61 in Q2 2025.